IN183798B - - Google Patents

Info

Publication number
IN183798B
IN183798B IN751CA1998A IN183798B IN 183798 B IN183798 B IN 183798B IN 751CA1998 A IN751CA1998 A IN 751CA1998A IN 183798 B IN183798 B IN 183798B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Andrew David Carison
Theodore Arsay Sheliga
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IN183798B publication Critical patent/IN183798B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN751CA1998 1997-04-28 1998-04-27 IN183798B (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28

Publications (1)

Publication Number Publication Date
IN183798B true IN183798B (cs) 2000-04-15

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
IN752CA1998 IN187157B (cs) 1997-04-28 1998-04-27
IN751CA1998 IN183798B (cs) 1997-04-28 1998-04-27

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IN752CA1998 IN187157B (cs) 1997-04-28 1998-04-27

Country Status (35)

Country Link
US (4) US6162629A (cs)
EP (2) EP0875563A3 (cs)
JP (2) JP4383546B2 (cs)
KR (2) KR100564189B1 (cs)
CN (2) CN1227025C (cs)
AR (2) AR012010A1 (cs)
AT (1) ATE285788T1 (cs)
AU (2) AU743531B2 (cs)
BR (2) BR9809292A (cs)
CA (2) CA2287267C (cs)
CO (2) CO4940438A1 (cs)
CZ (1) CZ298429B6 (cs)
DE (1) DE69828330T2 (cs)
DK (1) DK0875252T3 (cs)
EA (2) EA002149B1 (cs)
EG (1) EG23685A (cs)
ES (1) ES2234072T3 (cs)
HK (1) HK1016472A1 (cs)
HU (2) HU224826B1 (cs)
ID (2) ID23172A (cs)
IL (2) IL132325A (cs)
IN (2) IN187157B (cs)
MY (2) MY118591A (cs)
NO (2) NO995134L (cs)
NZ (2) NZ337828A (cs)
PE (2) PE84799A1 (cs)
PL (2) PL195090B1 (cs)
PT (1) PT875252E (cs)
SI (1) SI0875252T1 (cs)
SV (2) SV1998000051A (cs)
TR (2) TR199902529T2 (cs)
TW (2) TWI242443B (cs)
UA (2) UA55448C2 (cs)
WO (2) WO1998048822A1 (cs)
ZA (2) ZA983496B (cs)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199902529T2 (xx) 1997-04-28 2000-02-21 Eli Lilly And Company Etkinle�tirilmi� protein C form�lasyonlar�.
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
EP1128842B1 (en) * 1998-11-13 2006-03-15 Eli Lilly And Company Use of human protein c for the manufacture of a medicament for treating heparin-induced thrombocytopenia
EP1131091B1 (en) * 1998-11-20 2003-04-02 Eli Lilly And Company Treatment of viral hemorrhagic fever with protein c
CN1326357A (zh) * 1998-11-23 2001-12-12 伊莱利利公司 治疗镰刀形红细胞贫血病及地中海贫血病的方法
ATE264113T1 (de) * 1998-12-10 2004-04-15 Lilly Co Eli Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
JP2004511428A (ja) * 2000-05-24 2004-04-15 イーライ・リリー・アンド・カンパニー 凝固亢進状態を処置するための製剤および方法
KR100899970B1 (ko) 2001-02-19 2009-05-28 메르크 파텐트 게엠베하 Ｔ-세포 에피토프의 동정 방법 및 감소된 면역원성을 갖는분자의 제조를 위한 용도
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
EP1417055A4 (en) * 2001-07-19 2007-09-26 Dmi Biosciences Inc USE OF COPPER CHELATORS TO PREVENT THE INACTIVATION OF PROTEIN C
AU2002327649A1 (en) 2001-09-19 2003-04-01 Mcmaster University Treatment of sepsis with tafi
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
HUP0501111A2 (en) 2001-10-15 2007-12-28 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor
IL162239A0 (en) 2001-12-21 2005-11-20 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
WO2003075834A2 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Activated protein c formulations
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
PL376219A1 (en) * 2002-10-29 2005-12-27 Alza Corporation Stabilized, solid-state polypeptide particles
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
JP4658041B2 (ja) * 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
CN101426520A (zh) * 2004-03-17 2009-05-06 诺华疫苗和诊断公司 通过给予组织因子途径抑制剂（tfpi）治疗社区获得性重症肺炎
US20080305100A1 (en) * 2004-07-23 2008-12-11 Zlokovic Berislav V Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
AU2006261555A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy
EP2029740B1 (en) * 2006-05-31 2012-06-20 Genzyme Corporation Use of polysaccharides for promotion of enzymatic activity
US20100041600A1 (en) * 2006-06-09 2010-02-18 Russel James A Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
BRPI0808259A2 (pt) * 2007-03-05 2014-07-08 Cadila Healthcare Ltd "formulação, processo de liofilização, formulação liofilizada, e processo para preparar uma formulação liofilizada"
KR20100014674A (ko) * 2007-03-29 2010-02-10 아보트 러보러터리즈 결정성 항-사람 ｉｌ-12 항체
NZ585702A (en) * 2007-11-30 2013-08-30 Abbott Lab Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013151727A1 (en) 2012-04-03 2013-10-10 Smith Medical Asd, Inc. Heparin-bulking agent compositions and methods thereof
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
IN2014DN11181A (cs) 2012-07-04 2015-10-02 Univ Sydney
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015157791A1 (en) 2014-04-16 2015-10-22 The University Of Sydney Treatment of abnormal cutaneous scarring
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
KR20220165820A (ko) * 2016-06-01 2022-12-15 세르비에 아이피 유케이 리미티드 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
WO1991012320A1 (en) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Activated protein c with truncated light chain
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
TR199902529T2 (xx) * 1997-04-28 2000-02-21 Eli Lilly And Company Etkinle�tirilmi� protein C form�lasyonlar�.
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
CO4950523A1 (es) 2000-09-01
PL336420A1 (en) 2000-06-19
ES2234072T3 (es) 2005-06-16
CO4940438A1 (es) 2000-07-24
HUP0003401A3 (en) 2003-01-28
SI0875252T1 (en) 2005-06-30
CN1261280A (zh) 2000-07-26
ID23172A (id) 2000-03-23
PL336889A1 (en) 2000-07-17
EA199900980A1 (ru) 2000-04-24
ID22933A (id) 1999-12-16
NO995198L (no) 1999-10-25
WO1998048818A1 (en) 1998-11-05
UA73071C2 (en) 2005-06-15
ATE285788T1 (de) 2005-01-15
ZA983497B (en) 1999-10-25
JP4383547B2 (ja) 2009-12-16
UA55448C2 (uk) 2003-04-15
JP2001524111A (ja) 2001-11-27
BR9809292A (pt) 2000-07-04
PL195090B1 (pl) 2007-08-31
US6436397B1 (en) 2002-08-20
JP4383546B2 (ja) 2009-12-16
KR20010020242A (ko) 2001-03-15
HU224826B1 (en) 2006-02-28
EP0875563A2 (en) 1998-11-04
CN1227025C (zh) 2005-11-16
AU7161898A (en) 1998-11-24
MY118591A (en) 2004-12-31
DE69828330D1 (de) 2005-02-03
US6162629A (en) 2000-12-19
TWI242443B (en) 2005-11-01
AU740753C (en) 2002-10-10
HUP0100284A3 (en) 2003-08-28
HUP0100284A2 (hu) 2001-06-28
NZ337828A (en) 2001-06-29
KR100450856B1 (ko) 2004-10-02
CZ298429B6 (cs) 2007-10-03
ZA983496B (en) 1999-10-25
TR199902631T2 (xx) 2000-01-21
PE86299A1 (es) 1999-09-17
KR100564189B1 (ko) 2006-03-27
DE69828330T2 (de) 2005-10-13
PL195642B1 (pl) 2007-10-31
EP0875252A3 (en) 2000-07-26
EA199900979A1 (ru) 2000-06-26
IL132325A0 (en) 2001-03-19
EP0875563A3 (en) 2000-08-02
DK0875252T3 (da) 2005-04-25
AU740753B2 (en) 2001-11-15
HUP0003401A2 (hu) 2001-02-28
CA2288143C (en) 2012-08-21
WO1998048822A1 (en) 1998-11-05
PE84799A1 (es) 1999-09-16
IL132502A0 (en) 2001-03-19
SV1998000050A (es) 1999-01-13
NZ500346A (en) 2001-08-31
US6159468A (en) 2000-12-12
IL132325A (en) 2005-07-25
TR199902529T2 (xx) 2000-02-21
MY120984A (en) 2005-12-30
CZ381099A3 (cs) 2000-03-15
SV1998000051A (es) 1998-12-11
NO995134D0 (no) 1999-10-21
AU7258998A (en) 1998-11-24
EG23685A (en) 2007-05-09
CN1254284A (zh) 2000-05-24
BR9809304B1 (pt) 2011-02-08
KR20010020325A (ko) 2001-03-15
AU743531B2 (en) 2002-01-31
AR015598A1 (es) 2001-05-16
EP0875252B1 (en) 2004-12-29
EA002149B1 (ru) 2001-12-24
CN1235638C (zh) 2006-01-11
PT875252E (pt) 2005-03-31
CA2287267C (en) 2006-08-15
IN187157B (cs) 2002-02-16
CA2287267A1 (en) 1998-11-05
US6395270B1 (en) 2002-05-28
HK1016472A1 (en) 1999-11-05
TW585871B (en) 2004-05-01
BR9809304A (pt) 2000-10-17
CA2288143A1 (en) 1998-11-05
EP0875252A2 (en) 1998-11-04
EA004881B1 (ru) 2004-08-26
JP2001527543A (ja) 2001-12-25
NO995198D0 (no) 1999-10-25
NO995134L (no) 1999-12-21
AR012010A1 (es) 2000-09-13

Similar Documents

Publication Publication Date Title
IN183798B (cs)
IN1998CH01821A (cs)
IN190792B (cs)
ITPN970022A0 (cs)
IN187839B (cs)
IN187448B (cs)
ITRM970140V0 (cs)
ITPS970017V0 (cs)
ITMI970998A0 (cs)
IN188729B (cs)
IN188495B (cs)
IN183690B (cs)
CN3058000S (cs)
CN3057229S (cs)
CN3058533S (cs)
CN3058531S (cs)
CN3058462S (cs)
CN3058449S (cs)
CN3058320S (cs)
CN3058269S (cs)
CN3058162S (cs)
CN3058088S (cs)
CN3058057S (cs)
CN3058025S (cs)
CN3058984S (cs)